SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

ZYME

Zymeworks Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a material clinical validation of Zymeworks' ADC platform and significantly de-risks ZW191's development path. Traders should monitor upcoming Part 2a data for dose selection and potential partnership announcements, which could catalyze further upside. The broad activity across FRα expression levels increases commercial addressability.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$28.53
T+0 close · Apr 21, 2026 · via day close
Latest settled
−15.21%
T+60 · $24.19
Vs SPY
−19.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $28.53entry
  2. T+1 · 7mo ago −3.86%α −3.46% · $27.43
  3. T+5 · 7mo ago −3.08%α −3.14% · $27.65
  4. T+20 · 6mo ago −14.48%α −17.64% · $24.40
  5. T+60 · 4mo ago −15.21%α −19.99% · $24.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed objective response rate in platinum-resistant ovarian cancer at doses of 6.4–9.6 mg/kg, with durable responses and a manageable safety profile. The data support advancing ZW191 into later-stage development for ovarian and endometrial cancers, where treatment options are limited.

Key Facts

  • ZW191 showed a 61% confirmed objective response rate (cORR) in platinum-resistant ovarian cancer at 6.4–9.6 mg/kg dose range.
  • Median progression-free survival was 7.6 months; median duration of response not reached, indicating durability.
  • Activity was observed regardless of FRα expression, expanding potential patient population.
  • Safety profile was manageable, with 55% grade ≥3 treatment-emergent adverse events (mostly neutropenia, anemia, thrombocytopenia).
  • Part 2a of the trial (dose optimization) has completed enrollment; data will inform registration-enabling studies.

Financial Impact

Potential blockbuster value if ZW191 advances successfully, addresses large unmet need in ovarian and endometrial cancers with strong early efficacy.

pipeline valuefuture cash flowsmarket cap

Risk Factors

  • Phase 1 data are early and from a small cohort; efficacy may not hold in larger trials.
  • Safety concerns around neutropenia and anemia could limit dosing or require supportive care, affecting adoption.
  • Competitive ADCs in FRα space (e.g., Elahere) may create market headwinds despite broader activity.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278571

Track record

25 reports on ZYME

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026